每经AI快讯，润达医疗（SH 603108，收盘价：14.62元）12月16日晚间发布公告称，公司第五届第二十 七次董事会会议于2025年12月16日在上海市虹口区乍浦路89号星荟中心1座8楼公司会议室以现场及通讯 相结合的方式召开。会议审议了《关于公司2026年度日常关联交易预计的议案》等文件。 每经头条（nbdtoutiao）——中标企业频频弃标 大型医疗设备采购有何难言之隐？ 2025年1至6月份，润达医疗的营业收入构成为：商业占比93.82%，工业占比6.04%，其他业务占比 0.14%。 （记者 张明双） 截至发稿，润达医疗市值为88亿元。 ...

智通财经APP讯，固生堂(02273)发布公告，于2025年12月16日，该公司斥资1042.05万港元回购36.67万 股股份，每股回购价格为28.04-28.68港元。 ...

1 23 654 15 177 AA 近日，诊断影像服务运营商 Lumexa Imaging Holdings 在纳斯达克完成首次公开募股（IPO）。公司以每股 18.5 美元的价格发行 2500 万股普通股，合计募集资金约 4.63 亿美元（约合32.6亿人民币） ，规模显著高于最初约 2 亿美元的募资预期。IPO 完成后，公司市值约 17.5 亿美元 。 在当前医疗科技领域 IPO 叙事多围绕 AI、创新器械或突破性技术的背景下，Lumexa Imaging 的上市显得颇为"反常"：它既不是影像设备制造商，也不是影像 AI 公司，而是一家 典型的医疗服务运营商 。正是这种"非技术叙事"的定位，使其 IPO 更值得从产业基本面角度重新审视。 Nasdag Composite Vasdaq Marketsite Nosdag NasdaqMarket # L u m e x a I m a g i n g 是谁 ？ 从公司本质来看，Lumexa Imaging 并不生产设备、不研发核心算法，其核心业务是 在美国各地运营门诊影像诊断中心 ，向患者和医疗体系提供标准化影像检查服务。 公司前身为 US Radiol ...

Group 1 - The Nanchang Ganyi Hospital was fined 5,000 yuan for overcharging a patient for ambulance services, charging 28,000 yuan instead of the standard 10,672 yuan based on their public pricing [1][2] - The incident involved a 1,600-kilometer round trip for patient transport, with the hospital's public rate being 20 yuan per 3 kilometers, equating to 6.67 yuan per kilometer [1] - Following public outcry, the hospital refunded the excess charge of 17,328 yuan to the patient [1] Group 2 - The Nanchang Market Supervision Administration mandated the hospital to correct its pricing violations and imposed a fine based on the Price Law of the People's Republic of China [2] - The hospital was also found to have engaged in other illegal practices, including overcharging and using expired medications, leading to a total confiscation of 87,220.86 yuan [2]

Core Viewpoint - The article discusses the administrative penalty imposed on Nanchang Gan Medical Hospital for overcharging a patient for ambulance services, highlighting issues of price regulation and patient rights in the healthcare sector [1][2][3]. Group 1: Incident Overview - On April 8, 2025, an employee of Nanchang Gan Medical Hospital charged a patient 28,000 yuan for a 1,600-kilometer ambulance transfer, while the official rate should have been 10,672 yuan based on the hospital's published pricing [1]. - The hospital was fined 5,000 yuan for violating pricing regulations and was ordered to correct its pricing practices [2]. - The hospital refunded the excess charge of 17,328 yuan to the patient after the incident gained public attention [1][2]. Group 2: Regulatory Actions - The Nanchang Market Supervision Administration took action based on the violation of the Price Law, which mandates clear pricing and prohibits overcharging [2]. - In addition to the ambulance incident, the hospital faced penalties for other violations, including overcharging and using expired medications, totaling 87,220.86 yuan in fines and confiscated illegal gains [2]. - The Jiangxi Provincial Health Commission is conducting further investigations into the hospital's practices and has suspended its medical transport services pending the outcome [3].

证券之星消息，12月16日医疗服务板块较上一交易日下跌1.65%，C百奥领跌。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流出8.57亿元，游资资金净流入924.91万元，散户资 金净流入8.47亿元。医疗服务板块个股资金流向见下表： ...

Group 1 - The Nanchang Ganyi Hospital was fined 5,000 yuan for overcharging a patient for ambulance services, charging 28,000 yuan instead of the standard 10,672 yuan based on public pricing [1][2] - The incident involved a 1,600-kilometer round trip for patient transport, where the hospital's public rate was 20 yuan per 3 kilometers, equating to 6.67 yuan per kilometer [1] - Following public attention on the "expensive ambulance" incident, the hospital refunded the excess charge of 17,328 yuan to the patient [1] Group 2 - The Nanchang Market Supervision Administration mandated the hospital to correct its pricing violations and imposed a fine based on the Price Law of the People's Republic of China [2] - The hospital was also found to have engaged in other illegal practices, including overcharging and using expired medications, leading to a total confiscation of 87,220.86 yuan [2]

昭衍新药（603127）(06127)回落逾5%，月内累计涨幅仍超24%。截至发稿，跌5.53%，报20.5港元，成 交额1.51亿港元。 消息面上，根据北京商报，2025年12月9日实验猴价格呈加速上涨趋势，大约14万元/只。方正证券指 出，实验猴作为临床前安评的刚性资源，随着临床前CRO订单稳步回暖，需求提升；且供给侧短期扩 产难度较大，部分猴场表示产能已预定至2026年一季度，预计供需偏紧状态或将维持，短期价格有望进 一步上行。 该行指出，以昭衍新药为例，假设按照2024年实验猴均价计入公允价值8.49万/只，2025Q4价格提升至 14万/只，假设猴场出栏率为17%，按照已知23200只猴测算，毛估计(考虑新补进猴子及未成年&老龄猴 的影响)025年新增公允价值约2.2亿。 ...

来源：格隆汇APP 海吉亚医疗(6078.HK)盘初一度涨超6%，现报12港元，总市值74.5亿港元。消息上，海吉亚医疗昨日盘 后公告，公司认为股份目前的交易价格并未反映其内在价值或公司的实际业务前景。因此，公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币300百万元的总价格购回股份。未来，公司 还将视市场情况，持续优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的 资本配置安排。 ...

海吉亚医疗(6078.HK)盘初一度涨超6%，现报12港元，总市值74.5亿港元。消息上，海吉亚医疗昨日盘 后公告，公司认为股份目前的交易价格并未反映其内在价值或公司的实际业务前景。因此，公司董事会 已议决利用购回授权，以不时在公开市场上按不少于人民币300百万元的总价格购回股份。未来，公司 还将视市场情况，持续优化股东回报，在回购、分红及并购扩张中做出更高效的、更有利于股东价值的 资本配置安排。 ...